Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate with different glucocorticoid bridge regimens for pulmonary sarcoidosis
ChiCTR2600132472Phase 3Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate and prednisone acetate in pulmonary sarcoidosis (3 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Average change in predicted forced vital capacity percentage from baseline to week 24. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
methotrexateprednisone acetate
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on ChiCTR2600132472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132472.